SCHEMBL4976222

SCHEMBL4976222

CC(=O)c1cccc2ncn(CC(=O)Nc3cc(C#N)cc(C(F)(F)F)c3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.47
TAS2R14 Q9NYV8 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.41
HTT P42858 2/20 0.41
AR P10275 2/20 0.41
TMPRSS4 Q9NRS4 1/20 0.41
NR2E1 Q9Y466 1/20 0.41
P2RX1 P51575 2/20 0.40
LMNA P02545 3/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
AURKA O14965 1/20 0.39
KDR P35968 1/20 0.39
AURKB Q96GD4 1/20 0.39
RECQL P46063 1/20 0.39
POLB P06746 1/20 0.39
P2RX7 Q99572 1/20 0.39
DPP4 P27487 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4976902 0.88 RXFP1 (0.49) RXFP1SMN1; SMN2HTTTMPRSS4P2RX1
SCHEMBL4974004 0.85 RXFP1 (0.47) RXFP1TMPRSS4P2RX1GAAKDR
SCHEMBL4972906 0.85 RXFP1 (0.47) RXFP1SMN1; SMN2HTTNR2E1P2RX1
SCHEMBL4974973 0.84 SMN1; SMN2 (0.48) RXFP1TAS2R14SMN1; SMN2HTTAR
SCHEMBL4973402 0.79 TP53 (0.50) RXFP1SMN1; SMN2HTTLMNAPOLB
SCHEMBL4976395 0.79 RXFP1 (0.46) RXFP1TMPRSS4LMNAGAAKDR
SCHEMBL4465214 0.78 RXFP1 (0.47) RXFP1TMPRSS4LMNAGAAKDR
SCHEMBL3042696 0.78 RXFP1 (0.47) RXFP1TMPRSS4LMNAGAATSHR
SCHEMBL3032795 0.77 RXFP1 (0.59) RXFP1SMN1; SMN2ARLMNAGAA
SCHEMBL4973246 0.77 SMN1; SMN2 (0.66) RXFP1SMN1; SMN2HTTLMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 RXFP1 1473/4885TAS2R14 3398/4885SMN1; SMN2 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.